脑小血管病临床试验框架(FINESSE):一篇综述
脑小血管病(SVD)导致四分之一的卒中,是血管性认知障碍和痴呆最常见的病理基础。FINESSE在国际血管行为与认知障碍学会支持下,采用结构化德尔菲共识流程制定SVD临床试验设计推荐,涵盖研究人群选择、临床终点、脑影像替代指标、循环生物标志物、新型试验设计及基于遗传数据的治疗优先级。
要点
- SVD临床试验应纳入SVD特征明确的人群,因SVD机制与其他卒中亚型不同。
- 推荐涉及研究人群、临床终点、脑影像替代指标、循环生物标志物、新型设计及孟德尔随机化。
- 目前SVD有效治疗很少,FINESSE为试验设计提供框架。
核心结论
- FINESSE为目前有效治疗很少的SVD提供了试验设计推荐。
- 对疾病发病机制的新认识,尤其是近期遗传学研究,提供了可作为治疗靶点的新通路。
- 其他现有心血管干预是否对SVD(而非其他卒中亚型)特别有效仍不确定。
研究设计与样本
- FINESSE在国际血管行为与认知障碍学会支持下创建,汇集SVD试验方法学相关专家,采用结构化德尔菲共识流程制定推荐。
主要发现
- SVD导致四分之一的卒中,是血管性认知障碍和痴呆最常见的病理基础。
- SVD机制与其他卒中病因不同,SVD本身可由多种病理引起,最常见为动脉硬化和脑淀粉样血管病。
- 至今SVD中少有足够把握度的高质量随机临床试验,试验方法不一致使部分结果难以解释。
关键数值与推荐
- 推荐领域包括研究人群的最佳选择、临床终点的选择、脑影像作为替代结局指标的使用、循环生物标志物用于参与者选择及作为替代标志物、新型试验设计、利用遗传数据通过孟德尔随机化确定治疗药物的优先级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 至今SVD中少有足够把握度的高质量随机临床试验,试验方法不一致使部分结果难以解释。
- 其他现有心血管干预是否对SVD(而非其他卒中亚型)特别有效仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cerebral small vessel disease (SVD) causes a quarter of strokes and is the most common pathology underlying vascular cognitive impairment and dementia. An important step to developing new treatments is better trial methodology. Disease mechanisms in SVD differ from other stroke etiologies; therefore, treatments need to be evaluated in cohorts in which SVD has been well characterized. Furthermore, SVD itself can be caused by a number of different pathologies, the most common of which are arteriosclerosis and cerebral amyloid angiopathy. To date, there have been few sufficiently powered high-quality randomized clinical trials in SVD, and inconsistent trial methodology has made interpretation of some findings difficult. OBSERVATIONS: To address these issues and develop guidelines for optimizing design of clinical trials in SVD, the Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE) was created under the auspices of the International Society of Vascular Behavioral and Cognitive Disorders. Experts in relevant aspects of SVD trial methodology were convened, and a structured Delphi consensus process was used to develop recommendations. Areas in which recommendations were developed included optimal choice of study populations, choice of clinical end points, use of brain imaging as a surrogate outcome measure, use of circulating biomarkers for participant selection and as surrogate markers, novel trial designs, and prioritization of therapeutic agents using genetic data via Mendelian randomization. CONCLUSIONS AND RELEVANCE: The FINESSE provides recommendations for trial design in SVD for which there are currently few effective treatments. However, new insights into understanding disease pathogenesis, particularly from recent genetic studies, provide novel pathways that could be therapeutically targeted. In addition, whether other currently available cardiovascular interventions are specifically effective in SVD, as opposed to other subtypes of stroke, remains uncertain. FINESSE provides a framework for design of trials examining such therapeutic approaches.
引用
- Markus HS, van Der Flier WM, Smith EE, et al. Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE): A Review. JAMA Neurol. 2022. PMID: 35969390. doi:10.1001/jamaneurol.2022.2262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。